J&J Growth Plan Calls For Four Virology Filings In As Many Years
Executive Summary
Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7
You may also be interested in...
AcelRx’s Pain Drug Zalviso Delayed By Delivery Device Issues
FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.
J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs
While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year
J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs
While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year